Rawstron, A., Webster, N., Dalal, S., de Tute, R. M., Bell, S., Cairns, D. A., …Hillmen, P. (2023). Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. Blood, 142(Supplement 1), 632-632. https://doi.org/10.1182/blood-2023-187943